USA flag logo/image

An Official Website of the United States Government

THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3060
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3060
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
IMMUNOMEDICS, INC.
300 The American Road Morris Plains, NJ 07950-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THIS PROJECT WILL EVALUATE ANTIBODY-MEDIATED, POLYMER-BOUND YTTRIUM-90 AS A CANCER THERAPY AGENT. ANTIBODIES WILL BE COUPLED THROUGH ONE COVALENT BOND TO A SMALL POLYLYSINE UNIT. THE LATTER WILL CARRY, VIA A BIFUNCTIONAL COUPLING AGENT, MOLECULES OF THE TRIVALENT METAL CHELATING SIDEROPHORE, DEFEROXAMINE. EACH DEFEROXAMINE WILL BE COMPLEXED WITH A SINGLE ATOM OF YTTRIUM-90, A HIGH ENERGY BETA-EMITTER. THE OPTIMUM NUMBER OF DEFEROXAMINES, BINDABLE TO THE EPSILON AMINO GROUPS WILL BE DETERMINED AND UNREACTED AMINO GROUPS BLOCKED TO ENSURE NONINTERFERENCE IN ANTIBODY CONJUGATION. THE POLYLYSINE-DEFEROXAMINE LINKER USED IN THIS LABORATORY HAS BEEN SHOWN TO WORK VERY WELL IN SIMILAR SYSTEMS, AND WILL BE APPLIED HERE. IN THE SCHEME WE PROPOSE WE HAVE TWO DISTINCT ROUTES FOR COUPLING POLYMER DOSIMETRY AND BIODISTRIBUTION ASPECTS WILL BE INVESTIGATED TO DETERMINE THE STABILITY OF OUR SYSTEM IN VIVO, TO EVALUATE DOSE DELIVERY TO TUMOR

Principal Investigator:

Gary griffiths
PRINCIPAL INVESTIGATOR
2014564779

Business Contact:

Small Business Information at Submission:

Immunomedics, Inc.
100 Bergen Street Bldg. #5 Newark, NJ 07103

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No